Long-term L-3-n-butylphthalide pretreatment attenuates ischemic brain injury in mice with permanent distal middle cerebral artery occlusion through the Nrf2 pathway
L-3-n-butylphthalide (NBP), which is used for treatment of mild and moderate acute ischemic stroke, exerts its effects by modulating the Nrf2 pathway. However, it has not been established whether NBP exerts its preventive effects in high-risk ischemic stroke patients through the Nrf2 pathway. We inv...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-07-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844022011975 |
| _version_ | 1818503054096334848 |
|---|---|
| author | Mingying Sun Changchun Jiang Xiwa Hao Jiangxia Pang Chao Chen Wenping Xiang Jun Zhang Shijun Zhao Po Wang Shangyong Geng Hanzhang Wang Yuechun Li Baojun Wang |
| author_facet | Mingying Sun Changchun Jiang Xiwa Hao Jiangxia Pang Chao Chen Wenping Xiang Jun Zhang Shijun Zhao Po Wang Shangyong Geng Hanzhang Wang Yuechun Li Baojun Wang |
| author_sort | Mingying Sun |
| collection | DOAJ |
| description | L-3-n-butylphthalide (NBP), which is used for treatment of mild and moderate acute ischemic stroke, exerts its effects by modulating the Nrf2 pathway. However, it has not been established whether NBP exerts its preventive effects in high-risk ischemic stroke patients through the Nrf2 pathway. We investigated whether NBP exerts its preventive effects through the Nrf2 pathway in long-term NBP pretreated dMCAO mice models. Nrf2+/+ wild-type and Nrf2−/− knockout mice were randomized into the vehicle group (equal volume vegetable oil), NBP-low-dose group (20 mg/kg) and NBP-high-dose group (60 mg/kg). The drug was administered once daily by gavage for a month. Then, a permanent distal middle cerebral artery occlusion model (dMCAO) was established after pretreatment with NBP. Neurological deficits, cerebral infarct volumes, brain water contents, activities of SOD, GSH-Px and MDA levels were determined. Further, axonal injury and demyelination, expression levels of Nrf2, HO-1 and NQO1 in ischemic brains were determined. Long-term NBP pretreatment significantly improved neurological functions, reduced cerebral infarction volumes, reduced brain water contents, increased SOD, GSH-Px activities, decreased MDA contents, reduced neurological injuries, axonal damage as well as demyelination, while increasing Nrf2, HO-1 and NQO1 mRNA as well as protein expressions in dMCAO mice models. |
| first_indexed | 2024-12-10T21:18:42Z |
| format | Article |
| id | doaj.art-e5b6f208fde8451ba57a34680c1ce898 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-12-10T21:18:42Z |
| publishDate | 2022-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-e5b6f208fde8451ba57a34680c1ce8982022-12-22T01:33:13ZengElsevierHeliyon2405-84402022-07-0187e09909Long-term L-3-n-butylphthalide pretreatment attenuates ischemic brain injury in mice with permanent distal middle cerebral artery occlusion through the Nrf2 pathwayMingying Sun0Changchun Jiang1Xiwa Hao2Jiangxia Pang3Chao Chen4Wenping Xiang5Jun Zhang6Shijun Zhao7Po Wang8Shangyong Geng9Hanzhang Wang10Yuechun Li11Baojun Wang12Department of Neurology, Baotou Central Hospital, Inner Mongolia, China; Neurological Diseases Clinical Medicine Research Center, Inner Mongolia Autonomous Region, ChinaDepartment of Neurology, Baotou Central Hospital, Inner Mongolia, China; Neurological Diseases Clinical Medicine Research Center, Inner Mongolia Autonomous Region, China; Cerebrovascular Disease Institute, Inner Mongolia Autonomous Region, ChinaDepartment of Neurology, Baotou Central Hospital, Inner Mongolia, China; Neurological Diseases Clinical Medicine Research Center, Inner Mongolia Autonomous Region, China; Cerebrovascular Disease Institute, Inner Mongolia Autonomous Region, ChinaDepartment of Neurology, Baotou Central Hospital, Inner Mongolia, China; Neurological Diseases Clinical Medicine Research Center, Inner Mongolia Autonomous Region, China; Cerebrovascular Disease Institute, Inner Mongolia Autonomous Region, ChinaDepartment of Neurology, Baotou Central Hospital, Inner Mongolia, China; Neurological Diseases Clinical Medicine Research Center, Inner Mongolia Autonomous Region, China; Cerebrovascular Disease Institute, Inner Mongolia Autonomous Region, ChinaDepartment of Neurology, Baotou Central Hospital, Inner Mongolia, China; Neurological Diseases Clinical Medicine Research Center, Inner Mongolia Autonomous Region, China; Cerebrovascular Disease Institute, Inner Mongolia Autonomous Region, ChinaDepartment of Neurology, Baotou Central Hospital, Inner Mongolia, China; Neurological Diseases Clinical Medicine Research Center, Inner Mongolia Autonomous Region, China; Cerebrovascular Disease Institute, Inner Mongolia Autonomous Region, ChinaDepartment of Neurology, Baotou Central Hospital, Inner Mongolia, China; Neurological Diseases Clinical Medicine Research Center, Inner Mongolia Autonomous Region, China; Cerebrovascular Disease Institute, Inner Mongolia Autonomous Region, ChinaDepartment of Neurology, Baotou Central Hospital, Inner Mongolia, China; Neurological Diseases Clinical Medicine Research Center, Inner Mongolia Autonomous Region, China; Cerebrovascular Disease Institute, Inner Mongolia Autonomous Region, ChinaDepartment of Neurology, Baotou Central Hospital, Inner Mongolia, China; Neurological Diseases Clinical Medicine Research Center, Inner Mongolia Autonomous Region, China; Cerebrovascular Disease Institute, Inner Mongolia Autonomous Region, ChinaDepartment of Neurology, Baotou Central Hospital, Inner Mongolia, China; Neurological Diseases Clinical Medicine Research Center, Inner Mongolia Autonomous Region, China; Cerebrovascular Disease Institute, Inner Mongolia Autonomous Region, ChinaDepartment of Neurology, Baotou Central Hospital, Inner Mongolia, China; Neurological Diseases Clinical Medicine Research Center, Inner Mongolia Autonomous Region, China; Cerebrovascular Disease Institute, Inner Mongolia Autonomous Region, ChinaDepartment of Neurology, Baotou Central Hospital, Inner Mongolia, China; Neurological Diseases Clinical Medicine Research Center, Inner Mongolia Autonomous Region, China; Cerebrovascular Disease Institute, Inner Mongolia Autonomous Region, China; Corresponding author.L-3-n-butylphthalide (NBP), which is used for treatment of mild and moderate acute ischemic stroke, exerts its effects by modulating the Nrf2 pathway. However, it has not been established whether NBP exerts its preventive effects in high-risk ischemic stroke patients through the Nrf2 pathway. We investigated whether NBP exerts its preventive effects through the Nrf2 pathway in long-term NBP pretreated dMCAO mice models. Nrf2+/+ wild-type and Nrf2−/− knockout mice were randomized into the vehicle group (equal volume vegetable oil), NBP-low-dose group (20 mg/kg) and NBP-high-dose group (60 mg/kg). The drug was administered once daily by gavage for a month. Then, a permanent distal middle cerebral artery occlusion model (dMCAO) was established after pretreatment with NBP. Neurological deficits, cerebral infarct volumes, brain water contents, activities of SOD, GSH-Px and MDA levels were determined. Further, axonal injury and demyelination, expression levels of Nrf2, HO-1 and NQO1 in ischemic brains were determined. Long-term NBP pretreatment significantly improved neurological functions, reduced cerebral infarction volumes, reduced brain water contents, increased SOD, GSH-Px activities, decreased MDA contents, reduced neurological injuries, axonal damage as well as demyelination, while increasing Nrf2, HO-1 and NQO1 mRNA as well as protein expressions in dMCAO mice models.http://www.sciencedirect.com/science/article/pii/S2405844022011975Brain ischemiaL-3-n-butylphthalideNrf2 signaling pathwayOxidative stressNeuroprotection |
| spellingShingle | Mingying Sun Changchun Jiang Xiwa Hao Jiangxia Pang Chao Chen Wenping Xiang Jun Zhang Shijun Zhao Po Wang Shangyong Geng Hanzhang Wang Yuechun Li Baojun Wang Long-term L-3-n-butylphthalide pretreatment attenuates ischemic brain injury in mice with permanent distal middle cerebral artery occlusion through the Nrf2 pathway Heliyon Brain ischemia L-3-n-butylphthalide Nrf2 signaling pathway Oxidative stress Neuroprotection |
| title | Long-term L-3-n-butylphthalide pretreatment attenuates ischemic brain injury in mice with permanent distal middle cerebral artery occlusion through the Nrf2 pathway |
| title_full | Long-term L-3-n-butylphthalide pretreatment attenuates ischemic brain injury in mice with permanent distal middle cerebral artery occlusion through the Nrf2 pathway |
| title_fullStr | Long-term L-3-n-butylphthalide pretreatment attenuates ischemic brain injury in mice with permanent distal middle cerebral artery occlusion through the Nrf2 pathway |
| title_full_unstemmed | Long-term L-3-n-butylphthalide pretreatment attenuates ischemic brain injury in mice with permanent distal middle cerebral artery occlusion through the Nrf2 pathway |
| title_short | Long-term L-3-n-butylphthalide pretreatment attenuates ischemic brain injury in mice with permanent distal middle cerebral artery occlusion through the Nrf2 pathway |
| title_sort | long term l 3 n butylphthalide pretreatment attenuates ischemic brain injury in mice with permanent distal middle cerebral artery occlusion through the nrf2 pathway |
| topic | Brain ischemia L-3-n-butylphthalide Nrf2 signaling pathway Oxidative stress Neuroprotection |
| url | http://www.sciencedirect.com/science/article/pii/S2405844022011975 |
| work_keys_str_mv | AT mingyingsun longterml3nbutylphthalidepretreatmentattenuatesischemicbraininjuryinmicewithpermanentdistalmiddlecerebralarteryocclusionthroughthenrf2pathway AT changchunjiang longterml3nbutylphthalidepretreatmentattenuatesischemicbraininjuryinmicewithpermanentdistalmiddlecerebralarteryocclusionthroughthenrf2pathway AT xiwahao longterml3nbutylphthalidepretreatmentattenuatesischemicbraininjuryinmicewithpermanentdistalmiddlecerebralarteryocclusionthroughthenrf2pathway AT jiangxiapang longterml3nbutylphthalidepretreatmentattenuatesischemicbraininjuryinmicewithpermanentdistalmiddlecerebralarteryocclusionthroughthenrf2pathway AT chaochen longterml3nbutylphthalidepretreatmentattenuatesischemicbraininjuryinmicewithpermanentdistalmiddlecerebralarteryocclusionthroughthenrf2pathway AT wenpingxiang longterml3nbutylphthalidepretreatmentattenuatesischemicbraininjuryinmicewithpermanentdistalmiddlecerebralarteryocclusionthroughthenrf2pathway AT junzhang longterml3nbutylphthalidepretreatmentattenuatesischemicbraininjuryinmicewithpermanentdistalmiddlecerebralarteryocclusionthroughthenrf2pathway AT shijunzhao longterml3nbutylphthalidepretreatmentattenuatesischemicbraininjuryinmicewithpermanentdistalmiddlecerebralarteryocclusionthroughthenrf2pathway AT powang longterml3nbutylphthalidepretreatmentattenuatesischemicbraininjuryinmicewithpermanentdistalmiddlecerebralarteryocclusionthroughthenrf2pathway AT shangyonggeng longterml3nbutylphthalidepretreatmentattenuatesischemicbraininjuryinmicewithpermanentdistalmiddlecerebralarteryocclusionthroughthenrf2pathway AT hanzhangwang longterml3nbutylphthalidepretreatmentattenuatesischemicbraininjuryinmicewithpermanentdistalmiddlecerebralarteryocclusionthroughthenrf2pathway AT yuechunli longterml3nbutylphthalidepretreatmentattenuatesischemicbraininjuryinmicewithpermanentdistalmiddlecerebralarteryocclusionthroughthenrf2pathway AT baojunwang longterml3nbutylphthalidepretreatmentattenuatesischemicbraininjuryinmicewithpermanentdistalmiddlecerebralarteryocclusionthroughthenrf2pathway |